RxDoctor Payments Data

Alfred Brady, MD

Cardiovascular Disease · Beaumont, TXNPI 1841293909

Payments from drug & device makers

$8,285in general payments, 2019–2025

Across 63 payments — averaging $131.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$7K
  • Abbott$180
  • E.r. Squibb & Sons, L.L.C.$167
  • Inspire Medical Systems, Inc.$142
  • Merck$140
  • Akcea Therapeutics, Inc.$119
  • plus $655 from 14 others

What the payments were for

  • Food & beverage$1,40217%
  • Education$1,30016%
  • Other$5,58367%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,285 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$63,425
Medicare patients
1,057
Services billed
2,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$169,169
EntrestoSacubitril/Valsartan33$44,664
XareltoRivaroxaban28$21,695
MultaqDronedarone Hcl14$20,776
BrilintaTicagrelor18$15,676
Repatha SureclickEvolocumab13$6,792
Metoprolol Succinate162$3,418
Ezetimibe-SimvastatinEzetimibe/Simvastatin12$1,353
Rosuvastatin Calcium81$1,072
Amlodipine Besylate133$1,044
ClopidogrelClopidogrel Bisulfate74$1,025
Potassium Chloride42$946
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$918
Nebivolol Hcl12$812
Ranolazine ErRanolazine11$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$169,169153 claims
Johnson & JohnsonXarelto$70$21,69528 claims
Sanofi-aventis U.S. LLCMultaq$33$20,77614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →